Biscayne Neurotherapeutics scores $3 mln Series B
Miami-based Biscayne Neurotherapeutics, a Biscayne Pharmaceuticals spin-out and developer of biopharmaceutical assets that treat neurological disorders, has closed $3 million in Series B financing The investors included Quark Venture, GF Securities and Mesa Verde Venture Partners.
30 January 2017•1 min read
